Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
John W FunderPrince Henry's Institute, Clayton, Victoria, AustraliaAbstract: Spironolactone was first developed over 50 years ago as a potent mineralocorticoid receptor (MR) antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which is less potent but much mo...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-10-01
|
| Series: | Integrated Blood Pressure Control |
| Online Access: | http://www.dovepress.com/mineralocorticoid-receptor-antagonists-emerging-roles-in-cardiovascula-a14583 |